NCT01507402View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Healthy Volunteers
Interventions
DRUG

REGN1033(SAR391786)

Administration method A

DRUG

REGN1033(SAR391786)

Administration method B

DRUG

Placebo

(inactive substance)

Trial Locations (2)

47710

Evansville

Unknown

Honolulu

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY